趋化因子配体18在肝细胞癌中的表达及其对临床病理特征和预后的影响

肝脏 ›› 2018, Vol. 23 ›› Issue (2): 125-127.

趋化因子配体18在肝细胞癌中的表达及其对临床病理特征和预后的影响

吴旭波, 常奇蒙, 王建法, 胡志秋, 沈晓东, 张紫平

201199 上海复旦大学附属中山医院闵行分院肝胆胰外科

收稿日期:2017-11-21 出版日期:2018-02-28 发布日期:2020-05-18
通讯作者: 张紫平,Email:zzpmd68@live.cn

Expression of chemokine ligand-18 in hepatocellular carcinoma and its influence on the clinicopathological features and prognosis

WU Xu-bo, CHANG Qi-meng, WANG Jian-fa, HU Zhi-qiu, SHEN Xiao-dong, ZHANG Zi-ping.

Department of Hepatopancreatobiliary Surgery, Minhang Branch, Zhongshan Hospital, Fudan University, Shanghai 201199, China

Received:2017-11-21 Online:2018-02-28 Published:2020-05-18
Contact: ZHANG Zi-ping, Email: zzpmd68@live.cn

摘要/Abstract

摘要： 目的探讨趋化因子配体18(CCL18)在肝细胞癌中的表达及其对临床病理特征和预后的影响。方法选取40例肝细胞癌患者作为研究对象,选取肝细胞癌旁肝组织标本和因良性肝占位行手术切除的正常肝组织标本各40份作为对照。应用免疫组织化学法检测CCL18在肝细胞癌及正常肝组织中的表达,比较CCL18在各组中的阳性表达率。分析肝细胞癌组织中CCL18的阳性表达与临床病理特征的关系,应用Kaplan-Meier法分析CCL18表达对肝细胞癌预后的影响。结果 CCL18在肝细胞癌组织中的阳性表达率为72.5%(29/40),在癌旁肝组织中的阳性表达率为7.5%(3/40),在正常肝组织中的阳性表达率为5.0%(2/40),肝癌组织中CCL18的阳性表达率显著高于正常肝组织和癌旁肝组织(χ²=9.251,P<0.05)。随着病理分化程度的降低CCL18的阳性表达率显著增高,有病灶转移的患者中CCL18阳性表达率显著高于无病灶转移的患者。CCL18 阳性的肝细胞癌患者的无进展生存期和总生存期显著短于CCL18阴性的肝细胞癌患者。结论 CCL18在肝细胞癌组织中的阳性表达显著增强,且影响患者的预后,CCL18阴性表达的肝细胞癌患者具有更长的生存期。

关键词: 趋化因子配体-18;肝细胞癌;临床病理特征;预后

Abstract: Objective To investigate the expression and clinical significance of chemokine ligand-18 (CCL18) in hepatocellular carcinoma (HCC).Methods Forty patients with HCC in our hospital were enrolled. Normal liver tissues adjacent to HCC, as well as normal liver tissues resected from benign liver lesions, were selected as controls. Hepatic expression of CCL18 were detected using immunohistochemistry, and its relationship with clinicopathological features was analyzed. Effect of CCL18 on prognosis of HCC was analyzed using Kaplan-Meier method. Results The positive expression rates of CCL18 in HCC tissues, paracancerous tissues and normal liver tissues were 72.5%, 7.5% and 5.0%, respectively. CCL18 expression significantly increased in patients with poor pathological differentiation and metastasis. The progression-free survival and overall survival in CCL18 negative expression group were significantly higher than those in the positive expression group (P<0.05).Conclusion The positive expression rate of CCL18 was significantly higher in HCC than that in control cases, and closely related to the prognosis. HCC patients with negative hepatic CCL18 might have a longer survival.

Key words: Chemokine ligand-18, Hepatocellular carcinoma, Clinicopathological features, Prognosis

吴旭波, 常奇蒙, 王建法, 胡志秋, 沈晓东, 张紫平. 趋化因子配体18在肝细胞癌中的表达及其对临床病理特征和预后的影响[J]. 肝脏, 2018, 23(2): 125-127.

WU Xu-bo, CHANG Qi-meng, WANG Jian-fa, HU Zhi-qiu, SHEN Xiao-dong, ZHANG Zi-ping.. Expression of chemokine ligand-18 in hepatocellular carcinoma and its influence on the clinicopathological features and prognosis[J]. Chinese Hepatolgy, 2018, 23(2): 125-127.

参考文献

[1] Lin X, Chen L, Yao Y, et al. CCL18-mediated down-regulation of miR98 and miR27b promotes breast cancer metastasis. Oncotarget, 2015, 6: 20485-20499.
[2] Schraufstatter IU, Zhao M, Khaldoyanidi SK, et al. The chemokine CCL18 causes maturation of cultured monocytes to macrophages in the M2 spectrum. Immunology, 2012, 135: 287-298.
[3] Liang WG, Ren M, Zhao F, et al. Structures of human CCL18, CCL3, and CCL4 reveal molecular determinants for quaternary structures and sensitivity to insulin degrading enzyme. J Mol Biol, 2015, 427(6 Pt B):1345-1358.
[4] 张玮, 杨莹珠, 李力, 等. CCLl8 过表达对卵巢上皮性癌细胞生物学行为的影响. 中华妇产科杂志, 2013, 48: 528-531.
[5] Maghazachi AA. Role of chemokines in the biology of natural killer cells. Curr Top Microbiol Immunol, 2010, 341:37-58.
[6] Xu L, Kitade H, Ni Y, et al. Roles of chemokines and chemokine receptors in obesity-associated insulin resistance and nonalcoholic fatty liver disease. Biomolecules, 2015, 5: 1563-1579.
[7] Sorensen TL, Sellebjerg F, Jensen CV, et al. Chemokines CXCL10 and CCL2: differential involvement in intrathecal inflammation in multiple sclerosis. Eur J Neurol, 2001, 8: 665-672.
[8] 程琦, 施光峰. 趋化因子CX3CL1及其受体在肝脏炎症和纤维化中的作用. 中国肝脏病杂志, 2012, 4: 55-58.
[9] Wasmuth HE, Tacke F, Trautwein C. Chemokines in liver inflammation and fibrosis. Semin Liver Dis, 2010, 30: 215-225.
[10] Hou X, Zhang Y, Qiao H. CCL18 promotes the invasion and migration of gastric cancer cells via ERK1/2/NF-κB signaling pathway. Tumour Biol, 2016, 37: 641-651.
[11] Kollert F, Binder M, Probst C, et al. CCL18- potential biomarker of fibro-inflammatory activity in chronic periaortitis. J Rheumatol, 2012, 39: 1407-1412.
[12] 高进, 唐讳, 叶嘉罡, 等. 趋化因子配体18 及微血管密度在乳腺癌组织中的表达及意义. 中华临床医师杂志(电子版), 2013, 7: 566-569.
[13] Zohny SF, Fayed ST. Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer. Med Oncol, 2010, 27: 1246-1253.
[14] Hoffmann-Vold AM, Heiervang TA, Garen T, et al. High level of chemokine CCL18 is associated with pulmonary function deterioration, lung fibrosis progression and reduced survival in Systemic Sclerosis. Chest, 2016, 150:299-306.
[15] Hamai K, Iwamoto H, Ishikawa N, et al. Comparative study of circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as disease markers of idiopathic pulmonary fibrosis. Dis Markers, 2016, 2016:4759040.

编辑推荐 0

Metrics

阅读次数

全文

323

HTML			PDF

最新录用	在线预览	正式出版	最新录用	在线预览	正式出版
0	0	0	0	0	323

来源	本网站	其他网站

次数	321	2
比例	99%	1%

摘要

179

最新录用	在线预览	正式出版

0	0	179

	来源	本网站

	次数	179
	比例	100%